Oncogensis - Weir Flashcards

For each card in which the Gene Mutation is given, give the associated cancer diagnosis and treatment drug, otherwise just do what the card says.

1
Q

Define: Oncogenes

A

Genes in which mutations give rise to a gain of function or an enhanced level of function, leading to a malignancy. Mutated oncogenes are protooncogenes and usually encode growth or division promoting proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Define: Tumor Suppressor Genes

A

Usually encode negative regulators of growth and proliferation that protect cells from malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Li-Fraumeni Syndrome

A

Mutation in p53 (a TSG); no “brake” on the system (no other info given)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Cowden Syndrom

A

Mutation in PTEN (a TSG); removes a “brake” (no other info given)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

GIST (Gastrointestinal Stromal Tumor)

A

Due to mutation in c-Kit (an oncogene) (no other info given)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mutation in EGFR kinase

A

Important in many cancers but specifically for lung cancers; Erlontinib (Tarceva)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mutation in EML4-ALK

A

Lung Cancer; Crizotinib (Xalkori)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mutation in EGFR receptor signaling

A

Head and Neck Cancer (Tonsil Cancer example); Cetuximab (Erbitux)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Goal is to inhibit VEGF in what cancer? What is treatment?

A

Glioblastoma; Bevacizumab (Avastin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Mutation in a VHL (not exclusive, just example given)

A

Renal Cell Carcinoma; Treat with Sunitinib (Sutent) to inhibit VEGF kinases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

9:22 translocation

A

Chronic Myeloid Lukemia; treat with inhibition of bcr-abl tyrosine kinase (no drug name given)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do you treat Estrogen Receptor positive breast cancer?

A

Tamoxifen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What inhibits mTOR when inhibiting estrogen receptors no longer works?

A

Everolimus (Afinitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How do you treat (HER-2) Estrogen Receptor negative breast cancer?

A

Trastuzumab (Herceptin); then Pertuzumab when HER-2 inhibitor no longer works

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do you treat Prostate Cancer?

A

With the androgen receptor Enzalutamide (Zytiga)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

BRAF Mutation (B600)

A

Melanoma; Treat with Vemurafenib (Zelboraf)

17
Q

Mutation in Hedgehog system (PTCH Mutation)

A

Basal Cell Carcinomas; Treat with Vismodegib (Erivedge), a SMO inhibitor

18
Q

Many malignancies are caused by?

A

Mutation in oncogenes or TSGs

19
Q

Two inherited disorders predisposing to malignancies caused by mutations in TSHs are?

A

Li Fraumeni Syndrome and Cowden’s Syndrome

20
Q

One cancer accelerated by a c-Kit mutation is?

A

GIST (Gastrointestinal Stromal Tumor)

21
Q

Mutations in EGFR and ALK can lead to malignancies in a small percentage of what cancer?

A

Lung Cancer

22
Q

Usually multiple mutations are needed to overcome the body’s boundaries for what?

A

Cell Growth

23
Q

What can identify the mutation sites for many cancers and treat the problem specifically with targeted therapy?

A

Genomic Medicine

24
Q

Effective medicines have been made against specific targets in what cancers? 6 examples given

A

Breast, Lung, Head and Neck, Chronic Leukemias, Skin Cancers, and Brain Tumors

25
Q

What are very important targets in Breast and Prostate cancers?

A

Hormone Receptors

26
Q

Why are targeted treatments rarely curative?

A

When one pathway is targeted, mutations may develop to allow the cancer to progress around the therapy. Also, other pathways may increase to bypass the effect.